Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Lab values

• 1\. Planning to receive endovascular therapy;
  • 2\. mRS scores ≥2 points before the onset;
  • 3\. Receiving any antiplatelet therapy after the onset;
  • 4\. Bleeding or other pathological brain disorders, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis), identified by CT/MRI;
  • 5\. Pre-existing clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia;
  • 6\. Pre-existing atrial fibrillation or anticoagulant therapy (warfarin, heparin, thrombin inhibitors or factor Xa inhibitors);
  • 7\. Hepatic or renal insufficiency (hepatic insufficiency refers to the alanine transaminase (ALT) value \> 2 times the upper limit of normal value or aspartate aminotransferase (AST) times \> 2 times the upper limit of normal value; renal insufficiency refers to creatinine values \> 2 times the upper limit of normal value);
  • 8\. Allergic to Ticagrelor or Aspirin or thier components and excipients;
  • 9\. Women who are pregnant or breastfeeding, or those with negative pregnancy test records while refusing to use effective contraceptives;
  • 10\. Having participated investigational drugs or device tests within 30 days;
  • 11\. Being considered inappropriate to participate by researchers.

• 1\. 18-80 years old;
  • 2\. Clinical diagnosis of acute ischemic stroke;
  • 3\. Time from onset to treatment ≤6.0 hours;
  • 4\. Having received or planning to receive intravenous thrombolytic therapy;
  • 5\. NIHSS score of 4-10 points, and at least one of the 5th (upper limb exercise) or 6 th (lower limb exercise) scale is ≥1 point;
  • 6\. Signed informed consent.